Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ptTheragnostic

ptTheragnostic
M&A STATUS
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Provider of biotechnology services. The company focuses on the development of genomics-based personalized analysis for radiation sensitivity to optimize radiation treatment for cancer as well as chronic disease risk prediction.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Parent Company
DNAmito
Primary Office
  • Maastricht
  • Netherlands

ptTheragnostic Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore ptTheragnostic‘s full profile, request access.

Request full access to PitchBook

ptTheragnostic Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000000 000000 00 Venture Capital-Backed Louisville, KY 000.00 0000000000 000.00
To view this company’s complete list of competitors, request access »

ptTheragnostic Executive Team (4)

Name Title Board
Seat
Contact
Info
Bert Smeets Ph.D Chief Operating Officer
Erik Roelofs Chief Technical Officer
Philippe Lambin Ph.D Chief Scientific Officer & Co-Founder

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »